GTC
IOVA icon

Ghost Tree Capital’s Iovance Biotherapeutics IOVA Stock Holding History

Ghost Tree Capital’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-500,000
Closed -$9.54M – 49
2021
Q4 		$9.54M Buy
+500,000
New +$11M 3.42% 9
2020
Q1 		– Sell
-350,000
Closed -$9.69M – 58
2019
Q4 		$9.69M Buy
+350,000
New +$7.96M 1.84% 19

Other funds holding IOVA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Ghost Tree Capital's IOVA Position: Q3 2023 in Review

Ghost Tree Capital sold out of Iovance Biotherapeutics (IOVA) in Q3 2023, closing a stake of 100,000 shares — an estimated $704K sold.

Ghost Tree Capital first reported a position in IOVA in Q1 2015 and held it in 26 quarters. The position peaked at $23.2M in Q4 2020. 227 funds tracked by Wall St. Rank hold IOVA as of Q3 2023.

  • Ghost Tree Capital reported no remaining Iovance Biotherapeutics position as of Q3 2023 after selling out during the quarter.
  • Ghost Tree Capital sold 100,000 Iovance Biotherapeutics shares in Q3 2023, an estimated $704K.
  • Ghost Tree Capital first reported a position in Iovance Biotherapeutics in Q1 2015 and held it in 26 quarters.
  • Ghost Tree Capital's Iovance Biotherapeutics position peaked at $23.2M in Q4 2020.
  • 227 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q3 2023.

Based on Ghost Tree Capital's 13F filing for Q3 2023, filed 14 Nov 2023.